Synthon performed a large-scale, multicentre phase III study for glatiramer acetate 20 mg/mL and obtained marketing approval for the generic version in Europe in 2016 [1, 2]. However, in their patent applications, Teva claimed that an improvement made to the glatiramer acetate synthesis process, employing the use of chemical hydrogen bromide (HBr), was unique enough to warrant patent protection. There were three such HBr related patents approved initially and in defence of these, Teva filed injunctions and other legal measures against Synthon in 19 European countries.

With this TBA decision all injunctions against Synthon will be lifted and it will be able to market its generic version of glatiramer acetate across Europe. However, the patent for Copaxone 40 mg/mL (three times a week) does not expire in Europe until 2030 and this will continue to be prescribed to patients. The lower-cost generic version available to patients with recurrent MS will only be available as glatiramer acetate 20 mg/mL.   

Related articles
Follow-on versions of glatiramer acetate in Russia and Europe

Follow-on glatiramer acetate gains European approval

FDA approves first follow-on version of glatiramer acetate

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.